Pure Global
NCT06128915

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

State University of New York at Buffalo·Phase 4·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Aging
Drug/Device/Intervention
vaccine
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
State University of New York at Buffalo
Timeline & enrollment
Phase
Phase 4
Start date
Jan 08, 2024
End date
May 31, 2026
Enrollment
60 participants
Primary outcome

Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination

Summary

This study focuses on the role of neutrophils in shaping the adaptive immune response to the
 anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.

ICD-10 classifications
Alzheimer diseaseAgenesis and underdevelopment of noseAgenesis of lungAdult-onset Still diseaseChoroidal degeneration
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06128915
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06128915 through Pure Global AI's free database. This Phase 4 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Aging. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.